## IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GLUGAGON-LIKE : CIVIL ACTION

PEPTIDE-1 RECEPTOR AGONISTS :

(GLP-1 RAS) PRODUCTS : LIABILITY LITIGATION :

THIS DOCUMENT RELATES TO: : MDL No. 3094 : 24-md-3094

Alaimo v. Novo Nordisk A/S, et al.

Case No. 2:24-cv-00741

Gregory v. Novo Nordisk A/S, et al.

Case No. 2:24-cv-00707

Lott v. Novo Nordisk A/S, et al. : Case No. 2:24-cv-00692 :

ORDER

AND NOW, this \_\_\_\_\_\_ day of March, 2024, upon consideration of the Motion for *Pro Hac Vice* Admission of Sarah S. Ruane, Esquire (Doc. No. 32), it is **ORDERED** that the Motion (Doc. No. 32) is **GRANTED** and Sarah S. Raune, Esquire is admitted *pro hac vice* for this Litigation for the Plaintiffs named in the following actions:

- Alaimo v. Novo Nordisk A/S, et al., Case No. 2:24-cv-00741
- Gregory v. Novo Nordisk A/S, et al., Case No. 2:24-cv-00707
- Lott v. Novo Nordisk A/S, et al., Case No. 2:24-cv-00692

Counsel shall (i) familiarize and comport herself in accordance with the Pennsylvania Rules of Professional Conduct and the rules of this Court, and (ii) presenting counsel shall continue to have responsibility for this matter during its pendency before the Court. Pursuant to this Order, the above-named counsel shall be permitted to participate in all aspects of the instant litigation on behalf of her clients. <sup>1</sup>

BY/THE COURT:

GENE E.K. PRATTER

UNITED STATES DISTRICT JUDGE

Counsel must request access to ECF through a PACER account. Information about this process can be found on the Court's website by using the following link: https://www.paed.uscourts.gov/nextgencmecf.